TELO

MKT CAP:$48M

Telomir Pharmaceuticals, Inc. Common Stock

Market Cap

$48M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.38+$0.04 (+2.99%)

Apr 23, 2026

Company Details

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to fun...

CEO

Erez Aminov

IPO Date

Apr 9, 2019

Website

telomirpharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$10M

EPS (Diluted)

-$0.34

Free Cash Flow

-$4M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 17, 2026

$0EPS -$0.33

Q4 2025

Mar 17, 2026

$0EPS -$0.06

Q3 2025

Nov 10, 2025

$0EPS -$0.03

Q2 2025

Aug 14, 2025

$0EPS -$0.17

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$63.5K
Q2 22	$0	$0	-$70.1K
Q3 22	$0	$0	-$233.5K
Q4 22	$0	$0	-$487.1K
Q1 23	$0	$0	-$482.9K
Q2 23	$0	$0	-$1M
Q3 23	$0	$0	-$954.2K
Q4 23	$0	$0	-$1M
Q1 24	$0	$0	-$2M
Q2 24	$0	$0	-$1M
Q4 24	$0	$0	-$3M
Q1 25	$0	$0	-$2M
Q2 25	$0	$0	-$5M
Q3 25	$0	$0	-$1M
Q4 25	$0	$0	-$2M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$0	$0
Q2 22	$0	$0
Q3 22	-$82.4K	-$82.4K
Q4 22	-$255.8K	-$255.8K
Q1 23	-$735.7K	-$735.7K
Q2 23	-$33.6K	-$33.6K
Q3 23	-$2M	-$2M
Q4 23	-$1M	-$1M
Q1 24	-$2M	-$2M
Q2 24	-$2M	-$2M
Q4 24	-$605.8K	-$605.8K
Q1 25	-$863.1K	-$863.1K
Q2 25	-$696.4K	-$696.4K
Q3 25	-$927.3K	-$927.3K
Q4 25	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$5
Q1 24	$5
Q2 24	$0
Q4 24	$2
Q1 25	$0
Q2 25	$4
Q3 25	$5
Q4 25	$3

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+660.7%
Q2 23	—	+1935.8%
Q3 23	—	+308.6%
Q4 23	—	+121.4%
Q1 24	—	+296.8%
Q2 24	—	+3.4%
Q4 24	—	+204.5%
Q1 25	—	+102.8%
Q2 25	—	+164.6%
Q3 25	—	-22.2%
Q4 25	—	-26.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$0	—
Q2 24	$0	—
Q4 24	$2M	—
Q1 25	$1M	—
Q2 25	$0	—
Q3 25	$0	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$59.8K	—	$3.6K
Q2 22	$66.3K	$3.8K	—
Q3 22	$229.7K	$3.8K	—
Q4 22	$477.3K	$9.8K	—
Q1 23	$440.3K	$42.6K	—
Q2 23	$667.6K	$60.1K	—
Q3 23	$262.6K	—	$691.6K
Q4 23	$203.8K	—	$874.8K
Q1 24	$804.0K	$741.5K	—
Q2 24	$594.8K	$879.7K	—
Q4 24	$269.1K	—	$3M
Q1 25	$337.0K	—	$2M
Q2 25	$42.8K	$5M	—
Q3 25	$759.5K	$387.0K	—
Q4 25	$1M	—	$838.5K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$0	$0	$0
Q4 22	$1.4K	$0	$1.4K
Q1 23	$0	$2.8K	$2.8K
Q2 23	$14.6K	$0	$14.6K
Q3 23	$2.5K	$0	$2.5K
Q4 23	$1.2K	$0	$1.2K
Q1 24	$3M	$0	$3M
Q2 24	$2M	$0	$2M
Q3 24	$834.6K	$0	$834.6K
Q4 24	$1M	$0	$1M
Q1 25	$403.0K	$0	$403.0K
Q2 25	$754.3K	$0	$754.3K
Q3 25	$7M	$0	$7M
Q4 25	$7M	$0	$7M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	30M	—	—
Q2 22	30M	0.0%	—
Q3 22	30M	0.0%	—
Q4 22	30M	0.0%	—
Q1 23	30M	0.0%	0.0%
Q2 23	30M	0.0%	0.0%
Q3 23	30M	0.0%	0.0%
Q4 23	30M	0.0%	0.0%
Q1 24	29M	-1.1%	-1.1%
Q2 24	30M	+1.1%	0.0%
Q4 24	30M	-0.2%	-0.2%
Q1 25	30M	+0.8%	+0.5%
Q2 25	30M	+0.8%	+2.5%
Q3 25	31M	+3.4%	+4.8%
Q4 25	34M	+10.8%	+16.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$0	15
Q1 24	$0	15
Q2 24	$0	15
Q4 24	$0	5
Q1 25	$0	5
Q2 25	$0	5
Q3 25	$0	5
Q4 25	$0	30K

Revenue / Employee